Uncategorized

Collaboration aims to accelerate biomarker discovery, strengthen translational research capabilities, and support scalable clinical validation AUSTIN, TX AND CLEVELAND, OH / ACCESS Newswire / May 26, 2026 / Aspira Women’s Health Inc. (OTCQX:AWHL) (“Aspira” or the “Company”), a bio-analytical company focused on the development of AI-powered, noninvasive diagnostics for women’s health, and Cleveland Clinic have signed an agreement…

AUSTIN, TX / ACCESS Newswire / April 23, 2026 / Aspira Women’s Health Inc. (“Aspira”) (OTCQB:AWHL), an AI-enhanced bio-analytics company focused on the development of noninvasive gynecologic disease diagnostics and disease management tools, today announced it is completing the buildout of its molecular laboratory in Q2 2026, marking a major operational milestone that accelerates development and future commercialization…

AUSTIN, TX / ACCESS Newswire / November 14, 2025 / Aspira Women’s Health Inc. (“Aspira”) (OTCQX:AWHL), an AI enhanced bio-analytics based women’s health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three and nine-month periods ended September 30, 2025. September Q3 Highlights: Aspira reported relatively…

Aspira Executes New, Scalable Laboratory Services Agreement in One of the Largest Markets in the US AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / October 29, 2025 / Aspira Women’s Health Inc., abio-analytical-based women’s health company focused on gynecologic disease diagnostics, today announced it has executed a new laboratory services agreement with University of Texas Medical Branch…

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Aspira Women’s Health Inc. (OTCQX: AWHL), an AI enhanced bio-analytical based women’s health company, has qualified to trade on the OTCQX® Best Market. Aspira Women’s Health Inc. upgraded to OTCQX from the…

Aspira aims to develop a multi-marker miRNA blood test to aid in the detection of endometriosis AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research…

New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation (CLEP) approval allows for OvaWatch® to be marketed in New York State AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that…

SUMMARY: “Spoke” designation acknowledges Aspira’s position as an innovator in women’s health, and provides new opportunities for funding, thought leadership and networking with other healthcare industry leaders AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease…